We are live on ! Find out more
RNAZ icon

TransCode Therapeutics
RNAZ

5 hedge funds and large institutions have $105K invested in TransCode Therapeutics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 0 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 4 → 5 (+1)

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

0% less ownership

Funds ownership: 0% → 0% (-0%)

63% less capital invested

Capital invested by funds: $282K → $105K (-$176K)

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
–
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$90K
2
Renaissance Technologies
Renaissance Technologies
New York
+$56.2K
3
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$11.2K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$11.2K
5
HF
HRT Financial
New York
+$11.2K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$126K
2
UBS Group
UBS Group
Switzerland
-$45K
3
TCM
Tang Capital Management
California
-$42.2K
4
VF
Virtu Financial
New York
-$16K
5
Two Sigma Investments
Two Sigma Investments
New York
-$8.12K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$46.5K +$90K +8 New
Renaissance Technologies
2
Renaissance Technologies
New York
$31K +$56.2K +5 New
Geode Capital Management
3
Geode Capital Management
Massachusetts
$8.61K +$11.2K +1 New
CAPTRUST Financial Advisors
4
CAPTRUST Financial Advisors
North Carolina
$8.24K +$11.2K +1 New
HF
5
HRT Financial
New York
$5K +$11.2K +1 New
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$1.81K – – –
XT
7
XTX Topco
Cayman Islands
$1.77K – – –
UBS Group
8
UBS Group
Switzerland
$1.3K -$45K -4 Closed
TRCT
9
Tower Research Capital (TRC)
New York
$909 – – –
Bank of America
10
Bank of America
North Carolina
$266 – – –
Wells Fargo
11
Wells Fargo
California
$26 – – –
FPFS
12
First Personal Financial Services
North Carolina
$1 – – –
SM
13
Sabby Management
Florida
– -$126K -7 Closed
TCM
14
Tang Capital Management
California
– -$42.2K -2 Closed
VF
15
Virtu Financial
New York
– -$16K -1 Closed
Two Sigma Investments
16
Two Sigma Investments
New York
– -$8.12K – –
WAM
17
Warberg Asset Management
Illinois
– -$5.03K – –

RNAZ Hedge Fund Activity: Q4 2023 in Review

5 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q4 2023, worth a combined $105K — down 63% from $282K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new RNAZ positions and 4 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $90K. The largest seller was Sabby Management, exiting entirely with an estimated $126K sold.

  • 5 institutional investors held TransCode Therapeutics (RNAZ) as of Q4 2023, up from 4 in Q3 2023.
  • Funds reported $105K of TransCode Therapeutics stock for Q4 2023, down 63% quarter-over-quarter.
  • 5 funds opened new TransCode Therapeutics positions in Q4 2023 and 4 closed out, a net change of +1 holder.
  • The largest TransCode Therapeutics buyer in Q4 2023 was Citadel Advisors, an estimated $90K added.
  • The largest TransCode Therapeutics seller in Q4 2023 was Sabby Management, an estimated $126K sold.

Based on aggregated 13F filings for Q4 2023.